Bringing Science to Market: Commercializing from NIH Sbir Awards
37 Pages Posted: 9 Jun 2008 Last revised: 30 Nov 2022
Date Written: June 2008
Abstract
We offer empirical information on the correlates of commercialization activity for research projects funded through the U.S. National Institutes of Health's (NIH's) Small Business Innovation Research (SBIR) award program. Based on this analysis we suggest possible recommendations for improving this aspect of the performance of NIH's SBIR program. Specifically, we estimate a model of the probability of commercialization as a function of the project's ability to attract additional developmental funding, along with other control variables. We find that additional developmental funding from non-SBIR federal sources and from own internal sources are important predictors of commercialization success, relatively more so than additional developmental funding from venture capitalists. We also find, among other things, that university involvement in the underlying research increases the probability of commercialization. Thus, these factors should be considered by NIH when making awards, if increased commercialization is an objective.
Suggested Citation: Suggested Citation
Do you have negative results from your research you’d like to share?
Recommended Papers
-
Proofs and Prototypes for Sale: the Tale of University Licensing
-
Do Scientists Pay to Be Scientists?
By Scott Stern
-
Who is Selling the Ivory Tower? Sources of Growth in University Licensing
By Jerry G. Thursby and Marie C. Thursby
-
By Donald S. Siegel, David Waldman, ...
-
Putting Patents in Context: Exploring Knowledge Transfer from MIT
-
Intellectual Capital and the Firm: The Technology of Geographically Localized Knowledge Spillovers
By Lynne G. Zucker, Michael R. Darby, ...
-
By Scott Stern and Fiona Murray
-
Incentives and Invention in Universities
By Saul Lach and Mark A. Schankerman
-
Incentives and Invention in Universities
By Saul Lach and Mark A. Schankerman
-
Incentives and Invention in Universities
By Saul Lach and Mark A. Schankerman